Log In
Print
BCIQ
Print
Print this Print this
 

L-DOS47

Also known as: formerly DOS47

  Manage Alerts
Collapse Summary General Information
Company Helix BioPharma Corp.
DescriptionPlant-derived urease combined with a highly specialized antibody agent to identify lung adenocarcinoma cells
Molecular Target Not available
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Fusion protein
Latest Stage of DevelopmentPhase I/II
Standard IndicationNon-small cell lung cancer (NSCLC)
Indication DetailsTreat non-small cell lung cancer (NSCLC); Treat stage IV recurrent or metastatic non-squamous non-small cell lung cancer (NSCLC)
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today